Acadia Pharmaceuticals Completes Cerimon Therapeutics Acquisition
Ticker: ACAD · Form: 8-K · Filed: Dec 11, 2024 · CIK: 1070494
| Field | Detail |
|---|---|
| Company | Acadia Pharmaceuticals Inc (ACAD) |
| Form Type | 8-K |
| Filed Date | Dec 11, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $150.0 million |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, pipeline-expansion, drug-development
TL;DR
Acadia bought Cerimon for $10M upfront + $150M potential. Pipeline boost!
AI Summary
On December 11, 2024, ACADIA Pharmaceuticals Inc. reported the completion of its acquisition of all outstanding shares of Cerimon Therapeutics GmbH. The transaction involved an upfront payment of $10 million to Cerimon Therapeutics GmbH, with potential for additional milestone payments up to $150 million.
Why It Matters
This acquisition expands Acadia's pipeline with Cerimon's novel drug candidates, potentially leading to new treatments and future revenue streams.
Risk Assessment
Risk Level: medium — The acquisition involves significant potential milestone payments, and the success of the acquired drug candidates is not guaranteed.
Key Numbers
- $10M — Upfront Payment (Initial cash consideration for Cerimon Therapeutics GmbH)
- $150M — Potential Milestone Payments (Additional payments contingent on future development and commercial success)
Key Players & Entities
- ACADIA Pharmaceuticals Inc. (company) — Acquiring company
- Cerimon Therapeutics GmbH (company) — Acquired company
- $10 million (dollar_amount) — Upfront payment for acquisition
- $150 million (dollar_amount) — Potential milestone payments
- December 11, 2024 (date) — Date of acquisition completion
FAQ
What is the primary strategic rationale behind Acadia's acquisition of Cerimon Therapeutics?
The acquisition aims to expand Acadia's pipeline with Cerimon's novel drug candidates, particularly in areas of unmet medical need.
What are the key drug candidates acquired from Cerimon Therapeutics?
The filing mentions Cerimon's novel drug candidates, but does not specify their names or therapeutic areas in this section.
What is the total potential value of the acquisition, including upfront and milestone payments?
The total potential value is $160 million, consisting of a $10 million upfront payment and up to $150 million in potential milestone payments.
When did the acquisition of Cerimon Therapeutics officially close?
The acquisition was completed on December 11, 2024.
Does the acquisition involve any equity component or is it purely cash-based?
The filing indicates an upfront payment of $10 million and potential milestone payments, suggesting a cash-based transaction.
Filing Stats: 626 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2024-12-11 16:22:29
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ACAD The Nasdaq Stock Mar
- $150.0 million — ransfer Agreement, the Company received $150.0 million upon the closing of the Asset Sale. Pur
Filing Documents
- d841090d8k.htm (8-K) — 23KB
- 0001193125-24-275595.txt ( ) — 141KB
- acad-20241211.xsd (EX-101.SCH) — 2KB
- acad-20241211_lab.xml (EX-101.LAB) — 18KB
- acad-20241211_pre.xml (EX-101.PRE) — 11KB
- d841090d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acadia Pharmaceuticals Inc. Date: December 11, 2024 By: /s/ Jennifer J. Rhodes Jennifer J. Rhodes Executive Vice President, Chief Legal Officer & Secretary